<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918188</url>
  </required_header>
  <id_info>
    <org_study_id>NavyGHB-004</org_study_id>
    <nct_id>NCT02918188</nct_id>
  </id_info>
  <brief_title>Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD</brief_title>
  <official_title>Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent Chronic Graft-versus-host-disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navy General Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navy General Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study suggested that hydrogen has a potential as an effective and safe therapeutic agent
      on cGVHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will evaluate clinical response rate, time to treatment Failure (TTF),
      overall survival (OS), and toxicity in cGVHD patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2031</completion_date>
  <primary_completion_date type="Anticipated">January 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 months after date of start of Hydrogen</time_frame>
    <description>Overall Response Rate (ORR)is defined as an Objective improvement at sixth month, and includes at least 1 of the following criteria:
At least 50% reduction of body surface area involved; Reduction (at least 20%) of skin sclerosis, measured by Rodnan score Improvement&gt;1 point in functional pulmonary tests, evaluated by LFS score; &gt;50% steroid reduction (for at least 4 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to treatment Failure (TTF)</measure>
    <time_frame>participants will be followed for the duration of the 6 months of treatment, and for the follow-up for expected average of 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>participants will be followed for the duration of the 6 months of treatment, and for the follow-up for expected average of 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Hydrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrogen</intervention_name>
    <description>Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)</description>
    <arm_group_label>Hydrogen</arm_group_label>
    <other_name>Hydrogen-rich water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Male

          -  not pregnant female

          -  patients &lt;65 years old

          -  Diagnosis of cGVHD steroid refractory (no response after Prednisone â‰¥1mg/kg ) or
             steroid-dependent cGVHD (had an initial response followed by a cGVHD flare upon
             steroid taper)

          -  Patient intolerant to steroid therapy

        Exclusion Criteria:

          -  Patients with stable disease, not well controlled by the current treatment

          -  Pregnancy

          -  HIV positive

          -  Severe liver or renal impairment: serum creatinine &gt;2.5 mg/dl; serum bilirubin&gt;2.5
             mg/dl (without evidence of hepatic cGVHD)

          -  Uncontrolled malignancies including the persistence of the underlying malignancy
             before the Allogeneic Transplantation and the relapse of hematopoietic malignancy

          -  Any other investigational agents administered within last four weeks

          -  Cardiac insufficiency (&gt;grade II, New York Heart Association classification)

          -  Inability to comply with medical therapy or follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liren Qian, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Navy General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liren Qian, M.D.</last_name>
    <phone>+861066957676</phone>
    <email>qlr2007@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liren Qian, M.D.</last_name>
      <phone>+861066957676</phone>
      <email>qlr2007@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Navy General Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Liren Qian</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

